HGH Therapy
HGH Therapy | Testosterone Therapy | Anti-Aging Group @ www.antiaginggroup.com | Hormone Replacement Therapy Doctors | Stem Cell, Testosterone & Anti-Aging Treatments from the Leading Hormone Therapy Center
 
Search Website

Are you a good candidate for hormone therapy? Click to fill out our PRIORITY RESPONSE form and find out!

HGH Therapy & Testosterone Therapy @ AAG Health The Antiaging Group Age Management Medical Clinic - www.antiaginggroup.com | Hormone Replacement Therapy for Men & Women | HGH Growth Hormone Injections & Testosterone Injections for Low T Replacement.
COMPLETE THIS FORM FOR A FREE CONSULTATION- (more)
› GENDER › BODY STATS › CONTACT INFORMATION › ADDITIONAL INFORMATION
HGH Therapy & Testosterone Therapy
Man
HGH Therapy & Menopause Therapy
Woman
Age (35+ Only)
Height
Weight
Fitness Level
Name
E-mail
Daytime Phone
() -



Area of Interest
HRT History
Comments

Hormone Therapy News Articles

Hormone Therapy Articles @ AAG Health Anti-Aging Group Hormone Replacement Therapy Center Online. The Anti-Aging Group Doctors specialize in HGH, Human Growth Hormone Therapy | Testosterone Therapy for Low T with Testosterone, the HCG Diet Plan for Helping to Lose Weight, Age Management, Anti-Aging Treatments for Men and Women and other Bio-identical HRT Hormone Treatments for Menopause and Andropause, the Male Menopause @ www.antiaginggroup.com

Body Composition And Quality Of Life In Adults With Growth Hormone Deficiency

Articles: [ Prev 9 10 11 12 13 14 15 16 17 Next ]

Journal of Clinical Endocrinology

Ahmad AM, Hopkins MT, Thomas J, Ibrahim H, Fraser WD, Vora JP June 2001, Vol, 54 No. 6 709

Body Composition And Quality Of Life In Adults With Growth Hormone Deficiency; Effects Of Low-Dose Growth Hormone Replacement

Abstract

OBJECTIVE: Adult growth hormone deficiency (AGHD) is characterized by abnormalities in body composition and a poor preceived quality of life (QoL). Weight-based high-does growth hormone replacement (GHR) results in improvements in body composition and QoL in AGHD. However, a high patient percentage reported side-effects on high-dose GHR resulting in a high rate of patient withdrawal from growth hormone (GH) treatment. High-dose GH therapy also leads to supraphysiological serum insulin-like growth factor-1 (IGF-1) concentrations that have been associated with breast and prostate cancer, raising major concerns over the use of such high-dose GH regimen in AGHD. The aim of this study was to assess the effects of low-dose growth hormone replacement (GHR) on body composition and QoL as early as 1 and 3 months.

Study Design

A prospective, open treatment design study to determine the early effects of low-dose GH administration on body composition and QoL. GH was initiated at a daily does of 0.4-0.5 IU, and titrated up to achieve and maintain IGF-1 standard deviation score (IGF-1 SDS) between the median and upper end of the age-related reference range.

Patients

Forty-six, post pituitary surgery, severe AGHD patients (22 women), defined as peak GH response <9 mU/l to provocative testing. The mean age was 50.4 years (range 26-72). Forty-three patients required additional pituitary replacement hormones following pituitary surgery and were on optimal doses at recruitment.

Measurements

Body composition and QoL were assessed prior to GHR and subsequently at 1 and 3 months after initiating GHR. Body mass index (BMI) and waist hip ration (WHR) were calculated from measurements of height, weight, and waist and hip circumference, respectively. Bioelectrical impedance analysis (BIA) was used to determine body fat and lean body mass. QoL was assessed using the disease-specific 'QoL-assessment of growth hormone deficiency in adults (QoL-AGHDA)' questionnaire. Serum IGF-1 was measured at each visit to assess the adequacy of GHR.

Results

IGF-1 and IGF-1 SDS increased significantly at 1 and 3 months (P<0.001) after commencing GHR. The increase in IGF-1 (P<0.05) and IGF-1 SDS (P<0.01) was significant between 1 and 3 months in the absence of any significant increase in GH dose (P= ns) during this period. Eighty-five per cent of patients achieved IGF-1 SDS levels between median and upper end of the age-related reference range after 3 months of GHR, and no side-effects were reported during this period. There was a significant reduction in body fat percentage (BFP) from 36.1 +/- 9.1% at baseline to 34.9 +/- 9.3% (P<0.01) at 1 month and 34.1 +/- 9.2% (P<0.001) at 3 months. Body fat mass (BFM) reduced from 32.8 +/- 13.6 kg at baseline to 31.9 +/- 13.9 kg at 1 month (P<0.05) and 31.1 +/- 13.6 kg at 3 months (P< 0.001). These changes in BFP and BFM occurred in the absence of any significant change in BMI and WHR (P= ns). Lean body mass (LBM) was 55.9 +/- 11.1 kg at baseline and increased to 57.1 +/- 11.3 kg after 1 month (P<0.01) and to 57.6 +/- 11.5 kg (P<0.001) after 3 months of GHR. Significant improvement was observed in the perceived QoL with the AGHD assessment scores reducing from 13.3 +/- 6.4 to 11.5 +/- 6.6 within 1 month (P<0.01) and 10.0 +/- 6.6 at 3 months (P<0.001). There was no significant correlation between improvement in QoL and changes in body fat percentage (r=0.01 at 1 month and r=0.12 at 3 months, P=ns) or IGF-1 levels (r=0.04 and r=0.003, P=ns at 1 and 3 months, respectively). The improvement in the body composition and QoL was significant between 1 and 3 months.

Conclusions

Low-dose GHR improves body composition and QoL as early as 1 month after commencement and the beneficial effects continue at 3 months. Most importantly these changes occur in the absence of side-effects. We therefore suggest the use of low-dose GH therapy, maintaining IGF-1 between the median and upper end of the age-related reference range, for the treatment of AGHD.

Name:
Required
Email:
Required
Phone:
Required
( ) -
Evening Phone: ( ) -
Best Day To Call:
Best Time To Call:
Age:
(35+ Only)
Additional Comments

We Respect Your Privacy
The information you provide is solely used by AAG Health and will not be shared with anyone, period. View our privacy policy


Articles: [ Prev 9 10 11 12 13 14 15 16 17 Next ]

[ Bookmark this Page! ]


Related Hormone Resources:

Daniel Rudman, M.D., Medical College of Wisconsin. "The effects of six months of growth hormone on lean body mass and adipose-tissue mass were equivalent in magnitude to the changes incurred during 10 to 20 years of aging."

Known Potential Human Growth Hormone Benefits:
  • Improves Blood Fat Levels
       (Cholesterol, HDL, LDL)
  • Improves Depression
  • Improves Social Contact

Known Potential Testosterone Benefits:
  • Improves Memory
  • Improves Sexual Performance
  • Enhances Sex Drive

WorldHealth.net is a partner of the Anti-Aging Group Hormone Therapy Physicians and Doctors | HRT - Hormone Replacement Therapy Clinic specializing in Testosterone Treatment for Low-T & HGH - Human Growth Hormone Therapy @ www.antiaginggroup.com
NO PRESCRIPTION WILL BE PROVIDED UNLESS A CLINICAL NEED EXISTS BASED ON REQUIRED LAB WORK, PHYSICIAN CONSULTATION, PHYSICAL EXAMINATION AND CURRENT MEDICAL HISTORY. PLEASE NOTE, AGREEING TO LAB WORK AND A PHYSICAL EXAM DOES NOT GUARANTEE A FINDING OF CLINICAL NECESSITY AND A PRESCRIPTION.

NO claim or opinion on the AAG Health web-site is intended to be, or should be construed to be, medical advice.
Please consult with a healthcare professional before starting any therapeutic program.
AAG Health Clinic and/or it's physicians do not carry malpractice insurance.

Sitemap | Terms of Services | Technical Disclaimer | Credentials | Privacy Policy | Hormone Therapy
About Testosterone Therapy | About HGH Therapy

© Copyright 2001, 2003, 2005, 2008, 2010, 2011, 2012 AAG Health, LLC All Rights Reserved

The AAG Health Anti-Aging Group for Hormone Therapy @ www.antiaginggroup.com is Protected by Copyscape Plagiarism Checker